Cofirasersen

N/A

Report date: 2025/10/13 20:01:13
NME

Base Information

Drug NameCofirasersen
Drug Alias NameION-827359IONIS-ENAC-2.5RxIONIS-ENaCRx
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionEpithelial sodium channel blockers
TargetsEpithelial sodium channel
Therapy Area/IndicationsPulmonary Disease, Chronic ObstructiveCystic FibrosisBronchitis, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaHungaryGermany +[4] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesIonis Pharmaceuticals IncCystic Fibrosis Foundation Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesIonis Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsPulmonary Disease, Chronic ObstructiveCystic FibrosisBronchitis, Chronic

Other Information

ATC CodeN/A
Related LinksN/A